Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience

Moscarella, Elisabetta; Ielasi, Alfonso; Mussayev, Abdurashid; Montorfano, Matteo; Mullassari, Ajit; Martín, Pedro; Testa, Luca; Jose, John; Ninios, Vlasis; Toutouzas, K.; Giannini, Francesco; Kertész, Attila; Unić, Daniel; Nissen, Henrik; Ezhumalai, Babu; Boopathy, Nagendra; Amat‐Santos, Ignacio J.; Seth, Ashok; Bedogni, Francesco; Tespili, Maurizio

doi:10.1016/j.ijcard.2023.01.017

Cited by 8 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moscarella et al, conducted a multicenter observational study of 267 aortic and mitral ViV and valve-in-ring procedures, in which the VARC-3 post-procedural technical success rate was evaluated to be 98%. Furthermore, no cases of BHV failure were noted, despite a high rate of valvuloplasty performed prior to THV deployment in the mitral positions (18). In this case-series, the BE Myval THV was used on an off-label basis.…”

Section: Discussionmentioning

confidence: 92%

“…The optimal performance of this novel BE Myval THV could be related to the wider range of suitable THV sizes compared to other commercially available THVs (21). In particular, the intermediate sizes reduce the risks of both oversize or incomplete ViV "sealing" that can be associated with (i) free wall rupture, or (ii) significant PVL or premature THV dysfunction (18). Although tricuspid ViV procedure could be performed through the trans-jugular vein approach, we report cases through the trans-femoral route, and only one case was complicated by bleeding requiring surgery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up

Mussayev,

Alimbayev,

Tanaliev

et al. 2023

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

Generally, the dysfunction or failure of bioprosthetic heart valves (BHVs) is managed by replacement surgery. In the case of tricuspid valve dysfunction, re-do surgery is rarely attempted because of the critically high risk of developing pulmonary hypertension, pulmonary embolism, and intraoperative mortality. Hence, transcatheter tricuspid repair and replacement procedures are preferred. More recently, transcatheter valve-in-valve (ViV) treatments have gained importance because of their less invasiveness, especially for patients with prior surgeries. Encouraging evidence of the safety and effectiveness of a novel balloon-expandable (BE) transcatheter heart valve (THV)—the Myval THV—has been reported for ViV procedures. Here, we present a case-series of 5 patients, in whom tricuspid ViV procedure was performed using BE Myval THV, implanted supra-annularly by anchoring onto the deteriorated BHV. This case-series details the procedural steps to prevent in-hospital adverse events and early (30-day) mortality and the challenges during tricuspid ViV interventions.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%